Deep vein thrombosis - Combined oestrogen-progestin contraception Factor
Last reviewed for CCPS 22 December 2008.
Investigative Documents
Claimant Report - Combined Oestrogen-Progestin Contraception - Deep Vein Thrombosis [CR9305]
Preliminary questions [21247]
there is some evidence that combined oestrogen-progestin contraception may be a factor in the development of the condition under consideration.1169 — the veteran is a woman.
the veteran used combined oestrogen-progestin contraception for a period of at least three weeks within the 90 days before the clinical onset of the condition under consideration.21391 — the veteran has established the causal connection between combined oestrogen-progestin contraception and VEA service for the clinical onset of deep vein thrombosis.
21392 — the veteran has established the causal connection between combined oestrogen-progestin contraception and operational service for the clinical onset of deep vein thrombosis.
or
21393 — the veteran has established the causal connection between combined oestrogen-progestin contraception and eligible service for the clinical onset of deep vein thrombosis.
Clinical onset and operational service [21392]
the veteran's use of combined oestrogen-progestin contraception for a period of at least three weeks within the 90 days before the clinical onset of the condition under consideration was due to operational service.Clinical onset and eligible service [21393]
the veteran's use of combined oestrogen-progestin contraception for a period of at least three weeks within the 90 days before the clinical onset of the condition under consideration was due to eligible service.